NYU Langone’s Department of Child and Adolescent Psychiatry offers Dialectal Behavior Therapy- Adolescent (DBT-A) Program ...

San Juan Capistrano, California / Syndication Cloud / January 18, 2026 / Mission Prep Adolescence is a formative stage ...

FORT LAUDERDALE, FL - January 13, 2026 - PRESSADVANTAGE - Grace Point Treatment Center in Fort Lauderdale, Florida, has ...

Post-traumatic stress disorder (PTSD) is among the most challenging mental health conditions to treat effectively. While traditional therapies help many people, a significant portion continue to ...

(RTTNews) - Ion Beam Applications SA (IBAB.BR, IOBCF), on Friday, said it has signed a contract with the Catholic University of Korea's Seoul St. Mary's Hospital to install a Proteus PLUS proton ...

On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene ...

Oct 3 (Reuters) - Rocket Pharmaceuticals (RCKT.O), opens new tab said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.

Having already altered the journey of its rare disease gene therapy to a hoped-for FDA approval, Rocket Pharmaceuticals has now aborted the mission entirely. The biotech initiated a rolling biologics ...

The Only Murders in the Building star admitted that she has felt extremely hurt over people criticizing her due to her weight over the years. “I've dealt with a lot of weight issues in my life," ...

As nucleic acid–based therapeutics evolve and mature, so too must the analytical tools that are designed to characterize them. New microfluidic capillary electrophoresis (CE) methods that are designed ...

Management reiterated, "We are on target for BLA and MAA filings in 2026" for OCU400 and on track for BLA in 2027 for OCU410ST for Stargardt disease. Musunuri stated, "We plan to provide full 12-month ...

Please provide your email address to receive an email when new articles are posted on . This is the first biologics license application submitted for a gene-agnostic retinal disease gene therapy.